These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 24570209

  • 21. BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.
    Pyo JS, Sohn JH, Kang G.
    Endocr Pathol; 2015 Sep; 26(3):211-7. PubMed ID: 25957797
    [Abstract] [Full Text] [Related]

  • 22. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
    Paek SH, Kim BS, Kang KH, Kim HS.
    World J Surg Oncol; 2017 Nov 13; 15(1):202. PubMed ID: 29132392
    [Abstract] [Full Text] [Related]

  • 23. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies.
    Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E, degli Uberti EC.
    Eur J Endocrinol; 2009 Sep 13; 161(3):467-73. PubMed ID: 19574281
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of the Clinical Usefulness of BRAFV600E Mutation Analysis of Core-Needle Biopsy Specimens in Thyroid Nodules with Previous Atypia of Undetermined Significance or Follicular Lesions of Undetermined Significance Results.
    Choi SH, Baek JH, Lee JH, Choi YJ, Song DE, Chung KW, Kim TY, Shong YK.
    Thyroid; 2015 Aug 13; 25(8):897-903. PubMed ID: 25978151
    [Abstract] [Full Text] [Related]

  • 25. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
    Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, Kim SW.
    Clin Endocrinol (Oxf); 2006 Nov 13; 65(5):660-6. PubMed ID: 17054470
    [Abstract] [Full Text] [Related]

  • 26. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.
    Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M.
    Am J Surg Pathol; 2012 Jun 13; 36(6):844-50. PubMed ID: 22592144
    [Abstract] [Full Text] [Related]

  • 27. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
    Estrella JS, Tetzlaff MT, Bassett RL, Patel KP, Williams MD, Curry JL, Rashid A, Hamilton SR, Broaddus RR.
    Mol Cancer Ther; 2015 Dec 13; 14(12):2887-95. PubMed ID: 26438153
    [Abstract] [Full Text] [Related]

  • 28. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
    Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F.
    J Clin Endocrinol Metab; 2012 Dec 13; 97(12):4390-8. PubMed ID: 23066120
    [Abstract] [Full Text] [Related]

  • 29. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.
    Zhang X, Wang L, Wang J, Zhao H, Wu J, Liu S, Zhang L, Li Y, Xing X.
    Exp Mol Pathol; 2018 Aug 13; 105(1):153-159. PubMed ID: 30009773
    [Abstract] [Full Text] [Related]

  • 30. Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma: Combined Analysis of Ultrasonography, Fine-Needle Aspiration Biopsy, and BRAF V600E Mutation.
    Kim SK, Lee JH, Woo JW, Park I, Choe JH, Kim JH, Kim JS.
    Medicine (Baltimore); 2015 May 13; 94(21):e760. PubMed ID: 26020381
    [Abstract] [Full Text] [Related]

  • 31. BRAF p.Val600Glu (V600E) mutation detection in thyroid fine needle aspiration cell block samples: a feasibility study.
    Leslie C, Grieu-Iacopetta F, Richter A, Platten M, Murray J, Frost FA, Amanuel B, Kumarasinghe MP.
    Pathology; 2015 Aug 13; 47(5):432-8. PubMed ID: 26154146
    [Abstract] [Full Text] [Related]

  • 32. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma.
    Kim JK, Seong CY, Bae IE, Yi JW, Yu HW, Kim SJ, Won JK, Chai YJ, Choi JY, Lee KE.
    Ann Surg Oncol; 2018 Jun 13; 25(6):1775-1781. PubMed ID: 29611028
    [Abstract] [Full Text] [Related]

  • 33. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.
    Biomed Pharmacother; 2014 May 13; 68(4):413-7. PubMed ID: 24721322
    [Abstract] [Full Text] [Related]

  • 34. Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples.
    Dyhdalo K, Macnamara S, Brainard J, Underwood D, Tubbs R, Yang B.
    Cancer Cytopathol; 2014 Feb 13; 122(2):114-22. PubMed ID: 24150898
    [Abstract] [Full Text] [Related]

  • 35. VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients.
    Rashid FA, Tabassum S, Khan MS, Ansari HR, Asif M, Sheikh AK, Sameer Aga S.
    J Clin Lab Anal; 2021 Feb 13; 35(2):e23628. PubMed ID: 33305405
    [Abstract] [Full Text] [Related]

  • 36. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
    Jara SM, Bhatnagar R, Guan H, Gocke CD, Ali SZ, Tufano RP.
    Head Neck; 2015 Dec 13; 37(12):1788-93. PubMed ID: 24989827
    [Abstract] [Full Text] [Related]

  • 37. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.
    Colanta A, Lin O, Tafe L, Ghossein R, Nafa K, Mitchell T, Ladanyi M, Arcila M.
    Acta Cytol; 2011 Dec 13; 55(6):563-9. PubMed ID: 22156467
    [Abstract] [Full Text] [Related]

  • 38. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma.
    Qi W, Shi C, Zhang P, Feng L, Wang J, Chen D.
    Pathol Res Pract; 2020 Aug 13; 216(8):153037. PubMed ID: 32703500
    [Abstract] [Full Text] [Related]

  • 39. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR.
    Endocr Res; 2014 Aug 13; 39(4):189-93. PubMed ID: 24679337
    [Abstract] [Full Text] [Related]

  • 40. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY, Yoo JH, Park ES, Kim MK, Lee TJ, Cho BY, Chung YJ, Kang KH, Ahn HY, Kim HS.
    Pathol Res Pract; 2015 Feb 13; 211(2):162-70. PubMed ID: 25468810
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.